The global agricultural sector faces increasing pressure to enhance food security and adopt sustainable practices amidst climate change and rising consumer demand for high-quality, traceable produce. Regulatory bodies are pushing for reduced pesticide use, while competitive markets demand consistent yields and minimal crop loss. This technology directly addresses these challenges by enabling precision disease management, reducing reliance on chemical treatments, and ensuring crop quality and supply chain stability, making it a critical tool for modern farming operations worldwide.
Enables Early Detection: Detects buckwheat downy mildew pathogen in asymptomatic seeds or plants, allowing for early identification of infection sources and preventing widespread damage.
Ensures High Specificity: Utilizes specific oligonucleotide sequences to identify only the buckwheat downy mildew pathogen, significantly reducing misdiagnosis risk.
Facilitates Efficient Healthy Seed Selection: Enables efficient removal of infected seeds and plants, thereby improving the selection of healthy seeds and establishing stable cultivation environments.
This patent protects specific oligonucleotide sequences essential for detecting buckwheat downy mildew pathogen (Peronospora ducommeti) and their use in PCR-based detection methods. The claims were refined through examination, establishing a robust and stable right with low invalidation risk, having successfully overcome examiner objections.
This patent primarily covers the specific oligonucleotide sequences and PCR methods for detecting buckwheat downy mildew. White space exists in developing novel therapeutic or preventative treatments for the disease, or extending the detection methodology to other specific pathogens affecting buckwheat or other specialty crops.
Buckwheat downy mildew can cause 5%–20% yield loss. Assuming a domestic buckwheat production value of ~$200M (AI est.) and a 5% reduction in yield loss through early diagnosis and spread prevention, the potential loss avoidance is ~$10M (AI est.) annually. If an adopting enterprise captures 1% of this benefit, the estimated economic impact is ~$100K (AI est.) per year.
X: Early Disease Detection Capability
Y: Detection Accuracy and Specificity